Publication Information

{'id': 'https://openalex.org/W2286807907', 'doi': 'https://doi.org/10.1158/1535-7163.targ-09-cn08-03', 'title': 'Abstract CN08-03: Targeting topoisomerase II inhibitors to cancer cells via the polyamines transport system', 'display_name': 'Abstract CN08-03: Targeting topoisomerase II inhibitors to cancer cells via the polyamines transport system', 'publication_year': 2009, 'publication_date': '2009-12-01', 'ids': {'openalex': 'https://openalex.org/W2286807907', 'doi': 'https://doi.org/10.1158/1535-7163.targ-09-cn08-03', 'mag': '2286807907'}, 'language': 'en', 'primary_location': {'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1535-7163.targ-09-cn08-03', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S48437117', 'display_name': 'Molecular Cancer Therapeutics', 'issn_l': '1535-7163', 'issn': ['1535-7163', '1538-8514'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}, 'type': 'article', 'type_crossref': 'journal-article', 'indexed_in': ['crossref'], 'open_access': {'is_oa': False, 'oa_status': 'closed', 'oa_url': None, 'any_repository_has_fulltext': False}, 'authorships': [{'author_position': 'first', 'author': {'id': 'https://openalex.org/A5073920505', 'display_name': 'Christian Bailly', 'orcid': 'https://orcid.org/0000-0002-2973-9357'}, 'institutions': [{'id': 'https://openalex.org/I4210143394', 'display_name': 'Pierre Fabre (France)', 'ror': 'https://ror.org/04hdhz511', 'country_code': 'FR', 'type': 'company', 'lineage': ['https://openalex.org/I4210143394']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Christian Bailly', 'raw_affiliation_strings': ['Pierre Fabre Research Institute, Toulouse, France.'], 'affiliations': [{'raw_affiliation_string': 'Pierre Fabre Research Institute, Toulouse, France.', 'institution_ids': ['https://openalex.org/I4210143394']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5047450286', 'display_name': 'Anna Kruczynski', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210143394', 'display_name': 'Pierre Fabre (France)', 'ror': 'https://ror.org/04hdhz511', 'country_code': 'FR', 'type': 'company', 'lineage': ['https://openalex.org/I4210143394']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Anna Kruczynski', 'raw_affiliation_strings': ['Pierre Fabre Research Institute, Toulouse, France.'], 'affiliations': [{'raw_affiliation_string': 'Pierre Fabre Research Institute, Toulouse, France.', 'institution_ids': ['https://openalex.org/I4210143394']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5083741321', 'display_name': 'Jean‐Marc Barret', 'orcid': 'https://orcid.org/0000-0001-8085-3422'}, 'institutions': [{'id': 'https://openalex.org/I4210143394', 'display_name': 'Pierre Fabre (France)', 'ror': 'https://ror.org/04hdhz511', 'country_code': 'FR', 'type': 'company', 'lineage': ['https://openalex.org/I4210143394']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Jean-Marc Barret', 'raw_affiliation_strings': ['Pierre Fabre Research Institute, Toulouse, France.'], 'affiliations': [{'raw_affiliation_string': 'Pierre Fabre Research Institute, Toulouse, France.', 'institution_ids': ['https://openalex.org/I4210143394']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5057964990', 'display_name': 'Yves Guminski', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210143394', 'display_name': 'Pierre Fabre (France)', 'ror': 'https://ror.org/04hdhz511', 'country_code': 'FR', 'type': 'company', 'lineage': ['https://openalex.org/I4210143394']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Yves Guminski', 'raw_affiliation_strings': ['Pierre Fabre Research Institute, Toulouse, France.'], 'affiliations': [{'raw_affiliation_string': 'Pierre Fabre Research Institute, Toulouse, France.', 'institution_ids': ['https://openalex.org/I4210143394']}]}, {'author_position': 'middle', 'author': {'id': 'https://openalex.org/A5043928924', 'display_name': 'Thierry Imbert', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210143394', 'display_name': 'Pierre Fabre (France)', 'ror': 'https://ror.org/04hdhz511', 'country_code': 'FR', 'type': 'company', 'lineage': ['https://openalex.org/I4210143394']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Thierry Imbert', 'raw_affiliation_strings': ['Pierre Fabre Research Institute, Toulouse, France.'], 'affiliations': [{'raw_affiliation_string': 'Pierre Fabre Research Institute, Toulouse, France.', 'institution_ids': ['https://openalex.org/I4210143394']}]}, {'author_position': 'last', 'author': {'id': 'https://openalex.org/A5038509746', 'display_name': 'Nicolas Guilbaud', 'orcid': None}, 'institutions': [{'id': 'https://openalex.org/I4210143394', 'display_name': 'Pierre Fabre (France)', 'ror': 'https://ror.org/04hdhz511', 'country_code': 'FR', 'type': 'company', 'lineage': ['https://openalex.org/I4210143394']}], 'countries': ['FR'], 'is_corresponding': False, 'raw_author_name': 'Nicolas Guilbaud', 'raw_affiliation_strings': ['Pierre Fabre Research Institute, Toulouse, France.'], 'affiliations': [{'raw_affiliation_string': 'Pierre Fabre Research Institute, Toulouse, France.', 'institution_ids': ['https://openalex.org/I4210143394']}]}], 'institution_assertions': [], 'countries_distinct_count': 1, 'institutions_distinct_count': 1, 'corresponding_author_ids': [], 'corresponding_institution_ids': [], 'apc_list': None, 'apc_paid': None, 'fwci': 0.0, 'has_fulltext': False, 'cited_by_count': 0, 'citation_normalized_percentile': {'value': 0.0, 'is_in_top_1_percent': False, 'is_in_top_10_percent': False}, 'cited_by_percentile_year': {'min': 0, 'max': 64}, 'biblio': {'volume': '8', 'issue': '12_Supplement', 'first_page': 'CN08', 'last_page': '03'}, 'is_retracted': False, 'is_paratext': False, 'primary_topic': {'id': 'https://openalex.org/T11845', 'display_name': 'Cancer therapeutics and mechanisms', 'score': 0.9991, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, 'topics': [{'id': 'https://openalex.org/T11845', 'display_name': 'Cancer therapeutics and mechanisms', 'score': 0.9991, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}, {'id': 'https://openalex.org/T13160', 'display_name': 'Synthesis and Biological Evaluation', 'score': 0.9923, 'subfield': {'id': 'https://openalex.org/subfields/1605', 'display_name': 'Organic Chemistry'}, 'field': {'id': 'https://openalex.org/fields/16', 'display_name': 'Chemistry'}, 'domain': {'id': 'https://openalex.org/domains/3', 'display_name': 'Physical Sciences'}}, {'id': 'https://openalex.org/T10432', 'display_name': 'DNA and Nucleic Acid Chemistry', 'score': 0.9768, 'subfield': {'id': 'https://openalex.org/subfields/1312', 'display_name': 'Molecular Biology'}, 'field': {'id': 'https://openalex.org/fields/13', 'display_name': 'Biochemistry, Genetics and Molecular Biology'}, 'domain': {'id': 'https://openalex.org/domains/1', 'display_name': 'Life Sciences'}}], 'keywords': [{'id': 'https://openalex.org/keywords/camptothecin', 'display_name': 'Camptothecin', 'score': 0.8701618}, {'id': 'https://openalex.org/keywords/topoisomerase-inhibitor', 'display_name': 'Topoisomerase inhibitor', 'score': 0.8000952}, {'id': 'https://openalex.org/keywords/amsacrine', 'display_name': 'Amsacrine', 'score': 0.5005617}, {'id': 'https://openalex.org/keywords/topotecan', 'display_name': 'Topotecan', 'score': 0.44638443}], 'concepts': [{'id': 'https://openalex.org/C147897179', 'wikidata': 'https://www.wikidata.org/wiki/Q407828', 'display_name': 'Topoisomerase', 'level': 3, 'score': 0.91000926}, {'id': 'https://openalex.org/C2779682216', 'wikidata': 'https://www.wikidata.org/wiki/Q419964', 'display_name': 'Camptothecin', 'level': 2, 'score': 0.8701618}, {'id': 'https://openalex.org/C2778119113', 'wikidata': 'https://www.wikidata.org/wiki/Q418817', 'display_name': 'Etoposide', 'level': 3, 'score': 0.8050107}, {'id': 'https://openalex.org/C2778616834', 'wikidata': 'https://www.wikidata.org/wiki/Q281044', 'display_name': 'Topoisomerase inhibitor', 'level': 4, 'score': 0.8000952}, {'id': 'https://openalex.org/C56173144', 'wikidata': 'https://www.wikidata.org/wiki/Q1539893', 'display_name': 'Pharmacophore', 'level': 2, 'score': 0.5230533}, {'id': 'https://openalex.org/C2780500152', 'wikidata': 'https://www.wikidata.org/wiki/Q2784004', 'display_name': 'Amsacrine', 'level': 4, 'score': 0.5005617}, {'id': 'https://openalex.org/C86803240', 'wikidata': 'https://www.wikidata.org/wiki/Q420', 'display_name': 'Biology', 'level': 0, 'score': 0.45688254}, {'id': 'https://openalex.org/C98274493', 'wikidata': 'https://www.wikidata.org/wiki/Q128406', 'display_name': 'Pharmacology', 'level': 1, 'score': 0.45182037}, {'id': 'https://openalex.org/C2781209748', 'wikidata': 'https://www.wikidata.org/wiki/Q419953', 'display_name': 'Topotecan', 'level': 3, 'score': 0.44638443}, {'id': 'https://openalex.org/C185592680', 'wikidata': 'https://www.wikidata.org/wiki/Q2329', 'display_name': 'Chemistry', 'level': 0, 'score': 0.43339425}, {'id': 'https://openalex.org/C55493867', 'wikidata': 'https://www.wikidata.org/wiki/Q7094', 'display_name': 'Biochemistry', 'level': 1, 'score': 0.35988092}, {'id': 'https://openalex.org/C181199279', 'wikidata': 'https://www.wikidata.org/wiki/Q8047', 'display_name': 'Enzyme', 'level': 2, 'score': 0.26840156}, {'id': 'https://openalex.org/C2776694085', 'wikidata': 'https://www.wikidata.org/wiki/Q974135', 'display_name': 'Chemotherapy', 'level': 2, 'score': 0.21144226}, {'id': 'https://openalex.org/C54355233', 'wikidata': 'https://www.wikidata.org/wiki/Q7162', 'display_name': 'Genetics', 'level': 1, 'score': 0.13352427}], 'mesh': [], 'locations_count': 1, 'locations': [{'is_oa': False, 'landing_page_url': 'https://doi.org/10.1158/1535-7163.targ-09-cn08-03', 'pdf_url': None, 'source': {'id': 'https://openalex.org/S48437117', 'display_name': 'Molecular Cancer Therapeutics', 'issn_l': '1535-7163', 'issn': ['1535-7163', '1538-8514'], 'is_oa': False, 'is_in_doaj': False, 'is_core': True, 'host_organization': 'https://openalex.org/P4310320273', 'host_organization_name': 'American Association for Cancer Research', 'host_organization_lineage': ['https://openalex.org/P4310320273'], 'host_organization_lineage_names': ['American Association for Cancer Research'], 'type': 'journal'}, 'license': None, 'license_id': None, 'version': None, 'is_accepted': False, 'is_published': False}], 'best_oa_location': None, 'sustainable_development_goals': [{'score': 0.74, 'id': 'https://metadata.un.org/sdg/3', 'display_name': 'Good health and well-being'}], 'grants': [], 'datasets': [], 'versions': [], 'referenced_works_count': 0, 'referenced_works': [], 'related_works': ['https://openalex.org/W3094291022', 'https://openalex.org/W2429529028', 'https://openalex.org/W2400832343', 'https://openalex.org/W2118553080', 'https://openalex.org/W2104743561', 'https://openalex.org/W2098393177', 'https://openalex.org/W2062114187', 'https://openalex.org/W1988529521', 'https://openalex.org/W1587495423', 'https://openalex.org/W1541204074'], 'abstract_inverted_index': {'Abstract': [0], 'Topoisomerases': [1], 'inhibitors': [2, 116, 734], 'continue': [3], 'to': [4, 171, 207, 218, 239, 248, 260, 317, 345, 374, 378, 393, 417, 521, 617, 632, 651, 668, 695, 704, 741], 'play': [5], 'a': [6, 32, 69, 119, 220, 226, 274, 284, 325, 331, 342, 361, 379, 570, 586, 614, 625, 698, 722], 'major': [7], 'role': [8], 'in': [9, 29, 131, 269, 292, 421, 440, 460, 487, 504, 550, 583, 585, 621], 'cancer': [10, 365, 465, 635], 'chemotherapy.': [11], 'A': [12, 388, 645], 'large': [13, 587], 'number': [14], 'of': [15, 23, 26, 68, 71, 82, 111, 143, 184, 210, 213, 233, 277, 301, 464, 525, 546, 589, 700, 706, 718, 725, 732, 746], 'drug': [16], 'regimens,': [17], 'routinely': [18], 'used': [19, 130], 'for': [20, 50, 65, 235, 264, 327, 364, 450, 471, 561, 613, 658], 'the': [21, 47, 51, 66, 98, 107, 132, 138, 153, 158, 182, 192, 197, 208, 241, 293, 298, 302, 312, 368, 371, 376, 384, 395, 442, 501, 507, 522, 539, 541, 547, 551, 559, 607, 611, 716, 743], 'management': [22], 'many': [24, 488], 'forms': [25], 'solid': [27], 'tumors': [28, 489, 656], 'particular,': [30], 'include': [31], 'camptothecin': [33, 234], 'analog': [34], 'targeting': [35, 42, 165], 'topoisomerase': [36, 43, 127, 144, 526, 572], 'I': [37, 128, 168], 'or': [38, 94, 259], 'an': [39, 79, 477, 673], 'anthracycline': [40], 'derivative': [41, 53], 'II.': [44], 'This': [45, 514, 556, 593, 662], 'is': [46, 217, 338, 457, 509, 595, 606, 664, 735], 'case': [48], 'also': [49], 'podophyllotoxin': [52, 280], 'etoposide': [54], 'marketed': [55], 'more': [56, 113], 'than': [57], '25': [58], 'years': [59], 'ago': [60], 'and': [61, 109, 135, 162, 169, 195, 304, 307, 322, 439, 453, 473, 494, 543, 563, 578, 641, 690, 738], 'which': [62], 'remains': [63], 'prescribed': [64], 'treatment': [67, 659], 'variety': [70], 'malignancies,': [72], 'including': [73], 'leukaemia.': [74], 'These': [75], 'topoisomerases': [76, 115, 167, 733], 'poisons': [77, 129], 'form': [78], 'irreplaceable': [80], 'class': [81], 'antitumor': [83, 215, 581], 'agents,': [84], 'almost': [85], 'all': [86], 'derived': [87], 'from': [88, 92], 'natural': [89], 'products': [90], 'isolated': [91], 'plants': [93], 'microorganisms': [95], '(1).': [96], 'For': [97], 'past': [99], '20': [100], 'years,': [101], 'efforts': [102], 'have': [103, 149, 272], 'been': [104, 150, 484, 629, 649], 'concentrated': [105], 'on': [106, 469], 'discovery': [108], 'conception': [110], 'novel,': [112], 'potent,': [114], 'but': [117, 238, 506], 'with': [118, 181, 225, 243, 283, 341, 360, 654, 660, 697, 721], 'limited': [120], 'success.': [121], 'Camptothecins': [122], 'are': [123, 189, 409, 430, 448, 497, 693, 712], 'still': [124], 'unique': [125], 'among': [126], 'clinic.': [133], 'Anthracyclines': [134], 'podophyllotoxines': [136], 'remain': [137], 'two': [139, 175, 396], 'most': [140, 436], 'robust': [141], 'classes': [142], 'II': [145, 527, 573], 'modulators.': [146], 'Novel': [147, 178], 'compounds': [148, 179], 'introduced': [151], 'into': [152, 350, 565, 715], 'clinical': [154, 308, 598, 619, 646], 'pipeline,': [155], 'such': [156, 252, 406], 'as': [157, 253, 316, 407, 530, 569, 602], 'naphthyridine': [159], 'derivatives': [160, 281, 640], 'ARC-111': [161], 'voreloxin': [163], '(SNS-595),': [164], 'respectively': [166], 'II,': [170], 'cite': [172], 'only': [173], 'these': [174, 185, 677, 747], 'novel': [176, 211, 275, 332, 519, 723, 739], 'molecules.': [177, 412], 'interfering': [180], 'functions': [183, 568], 'DNA': [186, 423, 433, 532], 'manipulating': [187], 'enzymes': [188], 'continuously': [190], 'reported:': [191], 'alkaloids': [193], 'thaspine': [194], 'lamellarins,': [196], 'yeast-derived': [198], 'compound': [199, 549, 557], 'simocyclinone': [200], 'D-8,': [201], 'calothrixins,': [202], 'etc.': [203], 'An': [204], 'alternative': [205], 'approach': [206], 'design': [209, 294, 524, 542], 'categories': [212], 'topoisomerases-based': [214], 'agents': [216, 349, 748], 'maintain': [219], 'known': [221], 'chemical': [222, 245], 'archetype': [223], 'associated': [224], 'marked': [227], 'target': [228], 'selectivity': [229, 232, 326, 363], 'profile': [230], '(e.g.': [231], 'toposiomerase': [236], 'I)': [237], 'coupled': [240], 'pharmacophore': [242, 377], 'additional': [244], 'groups': [246], 'susceptible': [247], 'modulate': [249], 'target-independent': [250], 'properties': [251, 545], 'cell': [254, 285, 451, 576], 'selectivity,': [255], 'biodistribution,': [256], 'stability,': [257], 'pharmacokinetics,': [258], 'facilitate': [261], 'its': [262, 305, 319], 'handling': [263], 'example.': [265], 'With': [266], 'this': [267, 605, 709], 'idea': [268], 'mind,': [270], 'we': [271, 352, 536, 603, 680, 711], 'engineered': [273], 'group': [276], 'highly': [278, 410], 'potent': [279, 432, 531, 571], 'equipped': [282], 'delivery': [286, 333, 616], 'vector.': [287], 'Three': [288], 'points': [289], 'were': [290], 'considered': [291], 'strategy:': [295], '(i)': [296], 'improving': [297], 'aqueous': [299], 'solubility': [300], 'molecule': [303, 594, 609], 'pharmaceutical': [306], 'use,': [309], '(ii)': [310], 'reinforcing': [311], 'drug-target': [313], 'interaction,': [314], 'so': [315], 'consolidate': [318], 'DNA-damaging': [320], 'activity,': [321], '(iii)': [323], 'conferring': [324], 'tumor': [328, 566], 'cells': [329, 466, 671], 'via': [330], 'strategy.': [334], 'The': [335, 729], 'third': [336], 'point': [337], 'obviously': [339], 'essential,': [340], 'general': [343], 'applicability': [344], 'transform': [346], 'conventional': [347], 'cytotoxic': [348, 357, 727], 'what': [351], 'call': [353], '“targeted': [354], 'cytotoxics”,': [355], 'i.e.,': [356], 'molecules': [358], 'endowed': [359], 'pronounced': [362], 'cells.': [366, 490], 'At': [367], 'molecular': [369, 397, 502], 'level,': [370], 'concept': [372], 'consisted': [373], 'link': [375], 'polyamine': [380, 479, 639], 'guide': [381], 'providing': [382], 'simultaneously': [383], 'desired': [385], 'three': [386], 'properties.': [387, 404], 'suitable': [389], 'connector': [390], 'was': [391], 'constructed': [392], 'associate': [394], 'entities,': [398], 'without': [399], 'affecting': [400], 'their': [401], 'intrinsic': [402], 'recognition': [403], 'Polyamines,': [405], 'spermine,': [408], 'water-soluble': [411], 'As': [413, 600], 'cations,': [414], 'they': [415], 'binds': [416], 'nucleic': [418], 'acid': [419], 'polymers,': [420], 'particular': [422, 441], 'through': [424], 'minor': [425], 'groove': [426], 'interactions.': [427], 'Polyamine': [428, 491], 'conjugates': [429], 'usually': [431], 'binders.': [434], 'But': [435], 'importantly,': [437, 476], 'polyamines': [438, 470], 'naturally-occurring': [443], 'ones': [444], '(spermine,': [445], 'spermidine,': [446], 'putrescine),': [447], 'essential': [449], 'proliferation': [452], 'differentiation.': [454], 'Their': [455], 'metabolism': [456], 'frequently': [458], 'exacerbated': [459], 'tumors.': [461], 'Different': [462], 'types': [463], 'heavily': [467], 'rely': [468], 'growth': [472], 'survival.': [474], 'Most': [475], 'efficient': [478], 'transport': [480], 'system': [481], '(PTS)': [482], 'has': [483, 517, 628, 648], 'functionally': [485], 'characterized': [486], 'transporters,': [492], 'import': [493], 'export': [495], 'systems,': [496], 'poorly': [498], 'defined': [499], 'at': [500], 'level': [503, 699], 'human,': [505], 'PTS': [508, 560, 612], 'now': [510, 596, 713], 'well': [511, 666, 702], 'documented': [512], 'functionally.': [513], 'polyamine-based': [515], 'strategy': [516], 'open': [518], 'horizons': [520], 'rational': [523], 'inhibitors,': [528], 'acting': [529], 'damaging': [533], 'drugs.': [534], 'Here': [535], 'will': [537], 'present': [538], 'strategy,': [540], 'pharmacological': [544], 'lead': [548], 'series,': [552], 'designated': [553], 'F14512': [554], '(2).': [555], 'exploits': [558], 'entering': [562, 597, 714], 'accumulating': [564], 'cells,': [567, 636], 'poison,': [574], 'triggers': [575], 'death': [577], 'displays': [579], 'remarkable': [580], 'activities': [582], 'vivo,': [584], 'panel': [588], 'xenografts': [590], 'models': [591, 689], '(2,3).': [592], 'development.': [599], 'far': [601], 'know,': [604], 'first': [608], 'exploiting': [610], 'tumor-selective': [615], 'reach': [618], 'development': [620], 'oncology.': [622], 'In': [623], 'addition,': [624], 'functional': [626], 'screen': [627], 'set': [630], 'up': [631], 'identify': [633, 669], 'PTS(+)': [634, 655], 'using': [637], 'fluorescent': [638], 'cytometry': [642], 'assays': [643], '(4).': [644], 'procedure': [647], 'designed': [650], 'select': [652], 'patients': [653], 'eligible': [657], 'F14512.': [661], 'method': [663], 'particularly': [665], 'suited': [667], 'leukemia': [670, 686], 'expressing': [672], 'active': [674], 'PTS.': [675], 'Along': [676], 'lines,': [678], 'recently': [679], 'showed': [681], 'that': [682, 705], 'human': [683, 691], 'acute': [684], 'myeloid': [685], '(AML)': [687], 'animal': [688], 'samples': [692], 'sensitive': [694], 'F14512,': [696], 'activity': [701], 'superior': [703], 'etoposide.': [707], 'Through': [708], 'concept,': [710], 'field': [717], 'personalized': [719], 'medicine,': [720], 'generation': [724], 'cell-targeted': [726], 'agents.': [728], 'long': [730], 'history': [731], 'thus': [736], 'revivified': [737], 'opportunities': [740], 'increase': [742], 'therapeutic': [744], 'index': [745], 'can': [749], 'be': [750], 'envisioned.': [751], 'Citation': [752], 'Information:': [753], 'Mol': [754], 'Cancer': [755], 'Ther': [756], '2009;8(12': [757], 'Suppl):CN08-03.': [758]}, 'cited_by_api_url': 'https://api.openalex.org/works?filter=cites:W2286807907', 'counts_by_year': [], 'updated_date': '2024-12-07T19:46:07.573752', 'created_date': '2016-06-24'}